BioVaxys CEO James Passin joins Natalie Stoberman from the Proactive newsroom to discuss the company's acquisition of TAETSoftware, a Vancouver-based clinical studies management company engaged in the development and commercialization of the Trial Adverse Events Tracker (TAET) technology platform.

Passin says the acquisition of TAETCO provides BioVaxys with a third low-risk near-term revenue generating product, supporting its core business in cancer and viral vaccine development.

Contact Details

Proactive Canada

+1 604-688-8158


Copyright (c) 2023 TheNewswire - All rights reserved.